Evidence map›Paper›PMID 32975566›Full record

ArticleBioscience reports2020

Pathogenic LRRK2 requires secondary factors to induce cellular toxicity.

Evy Lobbestael, Chris Van den Haute, Francesca Macchi, Jean-Marc Taymans, Veerle Baekelandt

Open access · goldAbstract read
In one paragraph

Article in Bioscience reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Evy LobbestaelLaboratory for Neurobiology and Gene Therapy, Department of Neurosciences, KU Leuven, Herestraat 49 bus 1023, 3000 Leuven, Belgium.
Chris Van den HauteLaboratory for Neurobiology and Gene Therapy, Department of Neurosciences, KU Leuven, Herestraat 49 bus 1023, 3000 Leuven, Belgium.
Francesca MacchiInstituto Italiano di Tecnologia, via Morego 30, 16163 Genova, Italy.
Jean-Marc TaymansUniversité de Lille, Inserm, CHU Lille, UMR-S1172, LilNCog, Lille Neuroscience & Cognition, 59000 Lille, France.
Veerle BaekelandtLaboratory for Neurobiology and Gene Therapy, Department of Neurosciences, KU Leuven, Herestraat 49 bus 1023, 3000 Leuven, Belgium.
KU Leuven · BEInserm · FRItalian Institute of Technology · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pathogenic mutations in the leucine-rich repeat kinase 2 (LRRK2) gene belong to the most common genetic causes of inherited Parkinson's disease (PD) and variations in its locus increase the risk to develop sporadic PD. Extensive research efforts aimed at understanding how changes in the LRRK2 function result in molecular alterations that ultimately lead to PD. Cellular LRRK2-based models revealed several potential pathophysiological mechanisms including apoptotic cell death, LRRK2 protein accumulation and deficits in neurite outgrowth. However, highly variable outcomes between different cellular models have been reported. Here, we have investigated the effect of different experimental conditions, such as the use of different tags and gene transfer methods, in various cellular LRRK2 models. Readouts included cell death, sensitivity to oxidative stress, LRRK2 relocalization, α-synuclein aggregation and neurite outgrowth in cell culture, as well as neurite maintenance in vivo. We show that overexpression levels and/or the tag fused to LRRK2 affect the relocalization of LRRK2 to filamentous and skein-like structures. We found that overexpression of LRRK2 per se is not sufficient to induce cellular toxicity or to affect α-synuclein-induced toxicity and aggregate formation. Finally, neurite outgrowth/retraction experiments in cell lines and in vivo revealed that secondary, yet unknown, factors are required for the pathogenic LRRK2 effects on neurite length. Our findings stress the importance of technical and biological factors in LRRK2-induced cellular phenotypes and hence imply that conclusions based on these types of LRRK2-based assays should be interpreted with caution.

Indexed as

alpha-SynucleinAnimalsApoptosisCell Culture TechniquesCell Line, TumorCorpus StriatumDisease Models, AnimalFemaleGene Knockdown TechniquesGenetic VectorsHumansLeucine-Rich Repeat Serine-Threonine Protein Kinase-2MiceMutationNeuronal OutgrowthNeuronsalpha-SynucleinLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humanProtein AggregatesProtein Kinase InhibitorsRecombinant ProteinsSNCA protein, humancellular assaysleucine rich repeat kinaseneurite outgrowthParkinson's diseaseskein-like strucutres

Identifiers

PMID32975566
PMCPMC7560525
OpenAlexW3088419234

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.